Clinical Trial Update: Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating the Ga-68 labeled FF58 radiotracer in selected solid tumors overexpressing integrins has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Gastroesophageal Adenocarcinoma
• Glioblastoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• [68Ga]-FF58 (Gallium-68 labeled FF58 radiotracer)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glioblastoma Multiforme, Brain Neoplasms | EARLY_Phase 1 | Status: TERMINATED